Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.35
ACT's Cash to Debt is ranked higher than
51% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. ACT: 0.35 )
ACT' s 10-Year Cash to Debt Range
Min: 0.04   Max: 43.62
Current: 0.35

0.04
43.62
Equity to Asset 0.38
ACT's Equity to Asset is ranked higher than
50% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. ACT: 0.38 )
ACT' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.93
Current: 0.38

0.25
0.93
F-Score: 7
Z-Score: 2.89
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) -4.88
ACT's Operating margin (%) is ranked higher than
54% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. ACT: -4.88 )
ACT' s 10-Year Operating margin (%) Range
Min: -21.33   Max: 42.61
Current: -4.88

-21.33
42.61
Net-margin (%) -8.65
ACT's Net-margin (%) is ranked higher than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ACT: -8.65 )
ACT' s 10-Year Net-margin (%) Range
Min: -22.48   Max: 37.76
Current: -8.65

-22.48
37.76
ROE (%) -7.87
ACT's ROE (%) is ranked higher than
53% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. ACT: -7.87 )
ACT' s 10-Year ROE (%) Range
Min: -26.48   Max: 19.15
Current: -7.87

-26.48
19.15
ROA (%) -3.30
ACT's ROA (%) is ranked higher than
54% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. ACT: -3.30 )
ACT' s 10-Year ROA (%) Range
Min: -11.83   Max: 17.47
Current: -3.3

-11.83
17.47
ROC (Joel Greenblatt) (%) -14.30
ACT's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. ACT: -14.30 )
ACT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34.73   Max: 89.48
Current: -14.3

-34.73
89.48
Revenue Growth (%) 28.50
ACT's Revenue Growth (%) is ranked higher than
91% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ACT: 28.50 )
ACT' s 10-Year Revenue Growth (%) Range
Min: 6.4   Max: 54
Current: 28.5

6.4
54
EBITDA Growth (%) -2.90
ACT's EBITDA Growth (%) is ranked higher than
63% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ACT: -2.90 )
ACT' s 10-Year EBITDA Growth (%) Range
Min: -4.5   Max: 78
Current: -2.9

-4.5
78
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ACT Guru Trades in Q3 2013

RS Investment Management 180,834 sh (New)
Andreas Halvorsen 3,248,936 sh (+128.84%)
Mario Gabelli 39,659 sh (+61.87%)
Eric Mindich 500,000 sh (unchged)
Vanguard Health Care Fund 986,000 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 839,291 sh (-4.71%)
Scott Black 90,159 sh (-21.35%)
Francis Chou 76,705 sh (-58.63%)
Steven Cohen 42,936 sh (-89.47%)
Paul Tudor Jones 1,400 sh (-98.64%)
» More
Q4 2013

ACT Guru Trades in Q4 2013

George Soros 25,000 sh (New)
John Griffin 1,310,000 sh (New)
Jeremy Grantham 18,296 sh (New)
Private Capital 172,950 sh (New)
Diamond Hill Capital 93,086 sh (New)
Jim Simons 197,625 sh (New)
RS Investment Management 1,058,482 sh (+485.33%)
Steven Cohen 56,514 sh (+31.62%)
Paul Tudor Jones 1,700 sh (+21.43%)
Daniel Loeb 15,000 sh (unchged)
Vanguard Health Care Fund 986,000 sh (unchged)
Eric Mindich 500,000 sh (unchged)
Mario Gabelli 39,371 sh (-0.73%)
Pioneer Investments 806,036 sh (-3.96%)
Andreas Halvorsen 2,931,923 sh (-9.76%)
Scott Black 81,068 sh (-10.08%)
Francis Chou 35,400 sh (-53.85%)
» More
Q1 2014

ACT Guru Trades in Q1 2014

Daniel Loeb 2,500,000 sh (New)
John Paulson 300,000 sh (New)
Louis Moore Bacon 5,003 sh (New)
Joel Greenblatt 10,597 sh (New)
Ken Heebner 630,000 sh (New)
Steve Mandel 2,378,308 sh (New)
Leon Cooperman 264,093 sh (New)
Paul Tudor Jones 53,200 sh (+3029.41%)
Vanguard Health Care Fund 3,647,500 sh (+269.93%)
Jim Simons 401,936 sh (+103.38%)
Steven Cohen 83,190 sh (+47.2%)
George Soros 35,000 sh (+40%)
John Griffin 1,735,000 sh (+32.44%)
Private Capital 174,960 sh (+1.16%)
Eric Mindich 500,000 sh (unchged)
Francis Chou 35,400 sh (unchged)
RS Investment Management 939,682 sh (-11.22%)
Scott Black 67,883 sh (-16.26%)
Mario Gabelli 31,363 sh (-20.34%)
Pioneer Investments 620,874 sh (-22.97%)
Andreas Halvorsen 1,091,544 sh (-62.77%)
Diamond Hill Capital 18,613 sh (-80%)
Jeremy Grantham 1,306 sh (-92.86%)
Bill Nygren -693,000 sh (-9999%)
» More
Q2 2014

ACT Guru Trades in Q2 2014

Jean-Marie Eveillard 706,833 sh (New)
Kyle Bass 14,800 sh (New)
Bill Nygren 0 sh (+9999%)
Louis Moore Bacon 47,348 sh (+846.39%)
Leon Cooperman 619,919 sh (+134.74%)
Paul Tudor Jones 101,500 sh (+90.79%)
George Soros 63,831 sh (+82.37%)
Eric Mindich 692,000 sh (+38.4%)
Jim Simons 507,725 sh (+26.32%)
Mario Gabelli 36,165 sh (+15.31%)
Andreas Halvorsen 1,207,824 sh (+10.65%)
Steve Mandel 2,478,628 sh (+4.22%)
John Paulson 300,000 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Steven Cohen 25,000 sh (unchged)
Daniel Loeb 2,500,000 sh (unchged)
Diamond Hill Capital Sold Out
Joel Greenblatt Sold Out
Francis Chou Sold Out
Jeremy Grantham Sold Out
Private Capital 172,284 sh (-1.53%)
Vanguard Health Care Fund 3,359,667 sh (-7.89%)
RS Investment Management 845,397 sh (-10.03%)
Scott Black 48,858 sh (-28.03%)
Ken Heebner 370,000 sh (-41.27%)
Pioneer Investments 256,641 sh (-58.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2014-06-30 Add 134.74%1.03%$188.83 - $224.21 $ 226.9810%619919
Scott Black 2014-06-30 Reduce -28.03%0.42%$188.83 - $224.21 $ 226.9810%48858
Jean-Marie Eveillard 2014-06-30 New Buy0.38%$188.83 - $224.21 $ 226.9810%706833
Vanguard Health Care Fund 2014-06-30 Reduce -7.89%0.17%$188.83 - $224.21 $ 226.9810%3359667
George Soros 2014-06-30 Add 82.37%0.05%$188.83 - $224.21 $ 226.9810%63831
Joel Greenblatt 2014-06-30 Sold Out 0.03%$188.83 - $224.21 $ 226.9810%0
Daniel Loeb 2014-03-31 New Buy7.6%$165.64 - $227.26 $ 226.9815%2500000
Steve Mandel 2014-03-31 New Buy2.1%$165.64 - $227.26 $ 226.9815%2378308
Vanguard Health Care Fund 2014-03-31 Add 269.93%1.53%$165.64 - $227.26 $ 226.9816%3647500
John Griffin 2014-03-31 Add 32.44%0.96%$165.64 - $227.26 $ 226.9815%1735000
Leon Cooperman 2014-03-31 New Buy0.72%$165.64 - $227.26 $ 226.9815%264093
John Paulson 2014-03-31 New Buy0.3%$165.64 - $227.26 $ 226.9815%300000
Scott Black 2014-03-31 Reduce -16.26%0.24%$165.64 - $227.26 $ 226.9816%67883
Joel Greenblatt 2014-03-31 New Buy0.03%$165.64 - $227.26 $ 226.9815%10597
George Soros 2014-03-31 Add 40%0.02%$165.64 - $227.26 $ 226.9815%35000
Mario Gabelli 2014-03-31 Reduce -20.34%0.01%$165.64 - $227.26 $ 226.9815%31363
John Griffin 2013-12-31 New Buy2.3%$137.3 - $166.73 $ 226.9845%1310000
Scott Black 2013-12-31 Reduce -10.08%0.15%$137.3 - $166.73 $ 226.9845%81068
George Soros 2013-12-31 New Buy0.04%$137.3 - $166.73 $ 226.9845%25000
Scott Black 2013-09-30 Reduce -21.35%0.36%$122.08 - $144.3 $ 226.9870%90159
Mario Gabelli 2013-09-30 Add 61.87%0.01%$122.08 - $144.3 $ 226.9870%39659
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Actavis PLC

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Francis Chou Comments on Actavis Inc. - Sep 05, 2013

Another big winner was Actavis Inc. (ACT), formerly Watson Pharmaceutical. We first purchased Actavis in 2006 at $25. We kept buying the shares in 2007, and on June 30, 2013, it was priced at $126.22. It shows that when you are accurate in your estimation of intrinsic value and buy them at a significant discount, add in good management and respectable growth in intrinsic value, the investment works out really well. This is true even if you bought them when the market indices were trading at an all-time high. "Value traps" generally occur when you are wrong in your estimation of intrinsic value, pay too much and the company's intrinsic value is static and/or decreasing in value.

From Francis Chou's semi-annual report 2013.

Check out Francis Chou latest stock trades

Top Ranked Articles about Actavis PLC

Diamond Hill Capital Comments on Actavis PLC
We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. Read more...
Diamond Hill Capital Comments on Actavis Inc
Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues. Read more...
Top 5 Hedge Fund Net Buys
The recent top net buys of the hedge fund gurus were American Airlines (AAL), Actavis (ACT), Allegion (ALLE), Gilead Sciences (GILD), and Verizon (VZ). I found the net buys by using the S&P 500 Grid at GuruFocus. I adjusted the setting to include only hedge fund gurus and examined the results for both S&P 500 companies and non-S&P 500 companies. Read more...
Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN
According to GuruFocus list of 52-week highs; Actavis PLC, Novo Nordisk A/S, NXP Semiconductor NV and Wynn Resorts Ltd. have all reached their 52 week highs. Read more...
Francis Chou Comments on Actavis Inc.
Another big winner was Actavis Inc. (ACT), formerly Watson Pharmaceutical. We first purchased Actavis in 2006 at $25. We kept buying the shares in 2007, and on June 30, 2013, it was priced at $126.22. It shows that when you are accurate in your estimation of intrinsic value and buy them at a significant discount, add in good management and respectable growth in intrinsic value, the investment works out really well. This is true even if you bought them when the market indices were trading at an all-time high. "Value traps" generally occur when you are wrong in your estimation of intrinsic value, pay too much and the company's intrinsic value is static and/or decreasing in value. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 485.00
ACT's P/E(ttm) is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. ACT: 485.00 )
ACT' s 10-Year P/E(ttm) Range
Min: 11.01   Max: 485.71
Current: 485

11.01
485.71
P/B 4.10
ACT's P/B is ranked higher than
57% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACT: 4.10 )
ACT' s 10-Year P/B Range
Min: 1.08   Max: 5.9
Current: 4.1

1.08
5.9
P/S 3.70
ACT's P/S is ranked higher than
61% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ACT: 3.70 )
ACT' s 10-Year P/S Range
Min: 0.99   Max: 4
Current: 3.7

0.99
4
PFCF 25.00
ACT's PFCF is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 25.00 )
ACT' s 10-Year PFCF Range
Min: 6.64   Max: 111.88
Current: 25

6.64
111.88
EV-to-EBIT 96.85
ACT's EV-to-EBIT is ranked higher than
64% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. ACT: 96.85 )
ACT' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 140.5
Current: 96.85

8.8
140.5
PEG 254.16
ACT's PEG is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 254.16 )
ACT' s 10-Year PEG Range
Min: 4.27   Max: 285.5
Current: 254.16

4.27
285.5
Shiller P/E 413.00
ACT's Shiller P/E is ranked higher than
63% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. ACT: 413.00 )
ACT' s 10-Year Shiller P/E Range
Min: 15.1   Max: 413.29
Current: 413

15.1
413.29
Current Ratio 1.98
ACT's Current Ratio is ranked higher than
62% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. ACT: 1.98 )
ACT' s 10-Year Current Ratio Range
Min: 1.31   Max: 13.07
Current: 1.98

1.31
13.07
Quick Ratio 1.59
ACT's Quick Ratio is ranked higher than
66% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. ACT: 1.59 )
ACT' s 10-Year Quick Ratio Range
Min: 0.78   Max: 11.98
Current: 1.59

0.78
11.98

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.30
ACT's Price/DCF (Projected) is ranked higher than
84% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. ACT: 2.30 )
ACT' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 3.66
Current: 2.3

0.59
3.66
Price/Median PS Value 2.00
ACT's Price/Median PS Value is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ACT: 2.00 )
ACT' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 5.9
Current: 2

0.67
5.9
Price/Peter Lynch Fair Value 81.10
ACT's Price/Peter Lynch Fair Value is ranked higher than
84% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 81.10 )
ACT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 79.74
Current: 81.1

0.52
79.74
Earnings Yield (Greenblatt) 1.00
ACT's Earnings Yield (Greenblatt) is ranked lower than
55% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ACT: 1.00 )
ACT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 11.4
Current: 1

0.7
11.4
Forward Rate of Return (Yacktman) 7.35
ACT's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. ACT: 7.35 )
ACT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.1   Max: 16.6
Current: 7.35

-4.1
16.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:A60.Germany
Actavis, Inc. was is incorporated in 1985. The company's initial public offering was in February 1993. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. On October 31, 2012, Watson Pharmaceuticals, Inc. completed the acquisition of the company's Group. Watson Pharmaceuticals, Inc. common stock was traded on the New York Stock Exchange under the symbol WPI until close of trading on January 23, 2013, at which time Watson Pharmaceuticals, Inc. changed its corporate name to Actavis, Inc. and changed its ticker symbol to ACT. The Company develops and out-license generic pharmaceutical products primarily in Europe through its Medis third-party business. Following the renaming, the Company also changed the name of its three reporting segments. The Global Generics segment has become Actavis Pharma, Global Brands has become Actavis Specialty Brands, and Distribution has become Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment mainly distributes generic pharmaceutical products manufactured by third parties, as well as by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. The Anda Distribution segment operating results exclude sales by Anda of products developed, acquired, or licensed by the Company's Actavis Pharma and Actavis Specialty Brands segments. The Actavis Pharma segment develops, manufactures, markets, sells and distributes generic, branded generic and OTC products. The Actavis Specialty Brands segment includes key promoted products such as Rapaflo, Gelnique, Crinone, Trelstar, GeneressTM Fe, Androderm, and Kadian and a number of non-promoted products. All pharmaceutical manufacturers, including the Company, are subject to extensive, complex and evolving regulation by the federal government, principally the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for NYSE:ACT

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Actavis PLC Jul 25 2014 
George Soros Reveals His Largest Stake Jul 23 2014 
Diamond Hill Capital Comments on Actavis Inc Jun 26 2014 
Diamond Hill Small Cap Fund Commentary – First Quarter 2014 Jun 25 2014 
Oakmark Funds' Bill Nygren Buys 4 New Stocks May 29 2014 
Top 5 Hedge Fund Net Buys May 21 2014 
Dodge & Cox First Quarter 2014 Commentary May 06 2014 
Should You Buy Actavis? Mar 18 2014 
Giant Eyes for this Internet Television Giant - Sanford J. Colen Continues Long in Netflix Feb 15 2014 
Diamond Hill Capital Buys 12 New Stocks Feb 05 2014 

More From Our Partners
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog Aug 28 2014 - ZACKS

More From Other Websites
UCB Files Patent Infringement Lawsuit vs. Actavis Aug 28 2014
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 Aug 26 2014
Actavis Confirms Generic Neupro® Patent Challenge Aug 22 2014
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data Aug 21 2014
Pfizer back for AstraZeneca? Year-end move seen most likely Aug 21 2014
MEDIA-AstraZeneca is tougher target for possible new Pfizer bid - Bloomberg Aug 20 2014
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In... Aug 19 2014
Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 Aug 13 2014
ACTAVIS PLC Financials Aug 12 2014
ACTAVIS PLC Files SEC form 8-K, Other Events Aug 08 2014
Stocks Muted; Keurig Green Mountain Down After Hours Aug 06 2014
4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Aug 05 2014
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook Aug 05 2014
Actavis Guidance Disappoints; Akorn Beats And Raises Aug 05 2014
ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 05 2014
Actavis reports 2Q profit Aug 05 2014
Actavis reports 2Q profit Aug 05 2014
[$$] Actavis Swings to Profit Aug 05 2014
Drugmaker Actavis posts 34 pct rise in revenue Aug 05 2014
Q2 2014 Actavis plc Earnings Release - Before Market Open Aug 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK